https://www.thebodypro.com/category/dolutegravir-tivicay/tag/women

The Latest

pregnant stomach

This Week in HIV Research: Pregnancy Findings That Aren't About Dolutegravir

Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.

Fernanda Fernandes Fonseca and Meg Doherty at an IAS 2019 press conference

World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.

Mexico City's Downtown At Twilight

IAS 2019: What to Expect in HIV Science

Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.

Dolutegravir Preconception Signal: Time Is Up for Shoddy Surveillance Img

Dolutegravir Preconception Signal: Time Is Up for Shoddy Surveillance

"It is hard to imagine how in 2018 we could be in this situation where women with HIV are being so woefully underserved," Polly Clayden writes.

Integrase Inhibitors and Their Effectiveness and Safety in Women Img

Integrase Inhibitors and Their Effectiveness and Safety in Women

Results from two studies show that not only do integrase inhibitor-based regimens work well in women, but that they better tolerated than a regimen based on the protease inhibitor atazanavir.

Dolutegravir in Women Img

Dolutegravir in Women

In the Aria study, Triumeq showed statistical superiority over an atazanavir-containing regimen at 48 weeks in HIV-positive women.

Dolutegravir Is Superior to Boosted Atazanavir in Women in the ARIA Study Img

Dolutegravir Is Superior to Boosted Atazanavir in Women in the ARIA Study

Dolutegravir-based ART was superior to a boosted atazanavir-based regimen in treatment naive women at 48 weeks, according to data from the ARIA study presented at AIDS 2016.

Dolutegravir Superior in Women-Only Study Img

Dolutegravir Superior in Women-Only Study

On behalf of IFARA, Fred Schaich spoke with Kimberly Smith of ViiV Healthcare at this year's International AIDS Conference about 48-week data from the ARIA study of drug efficacy in women with HIV.